researchdrivelogo.jpg
Organ Care System Market for Heart Expected to Accumulate a Revenue of $37.2 Million by 2026, Growing at a Healthy CAGR of 16.5% | Reveals [90-Pages] by Research Dive
08 juin 2022 09h00 HE | Research Dive
New York, USA, June 08, 2022 (GLOBE NEWSWIRE) -- According to the latest report published by Research Dive, the global organ care system market for heart is anticipated to rise at a stable CAGR of...
Sanofi new_logo.jpg
Sanofi: Informations relatives au nombre de droits de vote et d'actions – Avril 2022
02 juin 2022 13h48 HE | Sanofi - Aventis Groupe
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés...
Sanofi new_logo.jpg
Sanofi: Information concerning the total number of voting rights and shares – April 2022
02 juin 2022 13h48 HE | Sanofi - Aventis Groupe
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement...
Featured Image for Filtration Group
Whirl-Pak® Joins Filtration Group
02 juin 2022 10h00 HE | Filtration Group
CHICAGO, June 02, 2022 (GLOBE NEWSWIRE) -- Filtration Group, an affiliate of Madison Industries, has acquired Whirl-Pak®, a leading provider of sterilized sampling and testing solutions, including...
Dyadic Logo Current.jpg
Dyadic to Present at 2022 Jefferies Healthcare Conference
02 juin 2022 09h27 HE | Dyadic International, Inc.
JUPITER, Fla., June 02, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...
22157.jpg
Outlook on the Anti-Inflammatory Drugs Global Market to 2027 - Rise in Commercialization of Anti-Inflammatory Drugs Presents Opportunities
02 juin 2022 04h08 HE | Research and Markets
Dublin, June 02, 2022 (GLOBE NEWSWIRE) -- The "Anti-Inflammatory Drugs Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering. The study...
Societal Color Logo and Tagline.png
Societal CDMO Selected By AmyriAD Pharma to Provide Clinical Trials Services to Support Pivotal Phase 3 Program For Alzheimer’s Disease Treatment, AD101
01 juin 2022 07h00 HE | Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., June 01, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving...
22157.jpg
Worldwide CNS Treatment and Therapy Industry to 2032 - by Depressive Disorder Type and Region
01 juin 2022 05h58 HE | Research and Markets
Dublin, June 01, 2022 (GLOBE NEWSWIRE) -- The "Global CNS Treatment and Therapy Market 2022-2032" report has been added to ResearchAndMarkets.com's offering. A recent market study published on the...
TIP_link_300x300.jpg
Fluorescent Immunoassay Market Size, $3.77Bn by 2028, 5.6% CAGR Led by ELISA Segment (56.12% Market Share in 2021): The Insight Partners
27 mai 2022 06h01 HE | The Insight Partners
NEw York, May 27, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Fluorescent Immunoassay Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product...
Elevar Logo for Common Use.png
Elevar Therapeutics Announces Rivoceranib Demonstrated Clinical Effectiveness in Patients with Progressive Recurrent or Metastatic Adenoid Cystic Carcinoma in a Phase 2 Trial
26 mai 2022 17h00 HE | Elevar Therapeutics
Results of open-label, multicenter study will be presented during a poster session at ASCO on June 6 Rivoceranib represents a potential new treatment option for patients with R/M ACC who have...